In recent years, Uterine fibroid embolization (UFE) have been highly deployed globally due to its minimally invasive technique. The technique incorporates the use of a real-time x-ray called fluoroscopy to guide the delivery of embolic agents to the uterus and fibroids. About 90% of women who have undergone UFE experience significant or complete resolution of their fibroid-related symptoms.
Frequently Asked Questions
The market is segmented based on Segmentation, By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment) – Industry Trends and Forecast to 2032
.
The Global Uterine Fibroid Embolization Devices Market size was valued at USD 5.70 USD Billion in 2024.
The Global Uterine Fibroid Embolization Devices Market is projected to grow at a CAGR of 4.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
